{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:07:28Z","timestamp":1791176848990,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.vaccine.2010.08.030","type":"journal-article","created":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T08:36:41Z","timestamp":1281861401000},"page":"6858-6867","source":"Crossref","is-referenced-by-count":215,"title":["Impact of vaccinating boys and men against HPV in the United States"],"prefix":"10.1016","volume":"28","author":[{"given":"Elamin H.","family":"Elbasha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik J.","family":"Dasbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2010.08.030_bib0005","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0010","article-title":"Human Papillomavirus","volume":"90","author":"IARC","year":"2007","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0015","series-title":"Vaccines for the 21st century: a tool for decisionmaking","author":"Institute of Medicine","year":"2000"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.030_bib0020","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3201\/eid0901.020168","article-title":"Cost effectiveness of a potential vaccine for human papillomavirus","volume":"9","author":"Sanders","year":"2003","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2010.08.030_bib0025","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1001\/jama.290.6.781","article-title":"Potential health and economic impact of adding a human papillomavirus vaccine to screening programs","volume":"290","author":"Kulasingam","year":"2003","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.030_bib0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2010.08.030_bib0035","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2009","journal-title":"N Eng J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2010.08.030_bib0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus (HPV) vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.030_bib0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1524-4733.2009.00512.x","article-title":"Age-based programs for vaccination against HPV","volume":"12","author":"Elbasha","year":"2009","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.vaccine.2010.08.030_bib0050","first-page":"387","article-title":"Cancer and infection: estimates of the attributable fraction in 1990","volume":"6","author":"Pisani","year":"1997","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"5A","key":"10.1016\/j.vaccine.2010.08.030_bib0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0002-9343(97)00177-0","article-title":"Epidemiology of genital human papillomavirus infection","volume":"102","author":"Koutsky","year":"1997","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.030_bib0060","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"10.1016\/j.vaccine.2010.08.030_bib0065","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s11538-008-9338-x","article-title":"A multi-type HPV transmission model: assessing the epidemiologic and economic impact of a quadrivalent HPV vaccine","volume":"70","author":"Elbasha","year":"2008","journal-title":"Bull Math Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.030_bib0070","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0025-5564(97)00014-X","article-title":"An age-structured model of pertussis transmission","volume":"145","author":"Hethcote","year":"1997","journal-title":"Math Biosci"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0075","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index detailed report tables (Tables 1A\u201323A). http:\/\/www.bls.gov\/cpi\/cpi_dr.htm; 2009 [accessed 15.10.09]."},{"key":"10.1016\/j.vaccine.2010.08.030_bib0080","series-title":"Cost-Effectiveness in health and medicine. Report of the panel on cost-effectiveness in health and medicine","year":"1996"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.030_bib0085","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2307\/1403510","article-title":"Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example","volume":"62","author":"Blower","year":"1994","journal-title":"Int Stat Rev"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.030_bib0090","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1524-4733.2001.45061.x","article-title":"Modeling for health care and other policy decisions: uses, roles, and validity","volume":"4","author":"Weinstein","year":"2001","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.030_bib0095","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves \u2013 facts, fallacies and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.030_bib0100","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","article-title":"Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds are expected to emerge?","volume":"7","author":"Eichler","year":"2004","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0105","doi-asserted-by":"crossref","first-page":"b3884","DOI":"10.1136\/bmj.b3884","article-title":"Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States","volume":"339","author":"Kim","year":"2009","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.vaccine.2010.08.030_bib0110","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3201\/eid1011.040222","article-title":"Evaluating human papillomavirus vaccination programs","volume":"10","author":"Taira","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"issue":"9","key":"10.1016\/j.vaccine.2010.08.030_bib0120","first-page":"626","article-title":"Patient adherence: a blind spot in cost-effectiveness analyses?","volume":"15","author":"Rosen","year":"2009","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0125","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.2105\/AJPH.2008.151332","article-title":"Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study","volume":"99","author":"Nelson","year":"2009","journal-title":"Am J Public Health"},{"key":"#cr-split#-10.1016\/j.vaccine.2010.08.030_bib0130.1","unstructured":"CDC's Advisory Committee on Immunization Practices (ACIP). Summary report, Atlanta, Georgia. http:\/\/www.cdc.gov\/vaccines\/recs\/acip\/downloads\/min-jun09.pdf;"},{"key":"#cr-split#-10.1016\/j.vaccine.2010.08.030_bib0130.2","unstructured":"June 24\u201326, 2009 [accessed 18.06.10]."},{"issue":"18","key":"10.1016\/j.vaccine.2010.08.030_bib0135","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1001\/jama.287.18.2382","article-title":"Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance","volume":"287","author":"Kim","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0140","unstructured":"Merck & Co., Inc. Unpublished data; 2009"},{"issue":"11","key":"10.1016\/j.vaccine.2010.08.030_bib0145","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1086\/375074","article-title":"The health and economic burden of genital warts in a set of private U.S","volume":"36","author":"Insinga","year":"2003","journal-title":"Health Plans Clin Infect Dis"},{"issue":"35","key":"10.1016\/j.vaccine.2010.08.030_bib0150","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1016\/j.vaccine.2008.06.045","article-title":"The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination","volume":"26","author":"Chesson","year":"2008","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2010.08.030_bib0155","doi-asserted-by":"crossref","first-page":"500.e1","DOI":"10.1016\/j.ajog.2008.03.064","article-title":"The economic burden of noncervical human papillomavirus disease in the United States","volume":"198","author":"Hu","year":"2008","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.08.030_bib0160","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0272989X07302128","article-title":"Abnormal outcomes following cervical cancer screening: event duration and health utility loss","volume":"27","author":"Insinga","year":"2007","journal-title":"Med Decis Making"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0165","series-title":"Proceedings of the 21st international papillomavirus conference, Mexico","article-title":"Patient preferences for health states related to HPV infection: visual analog scales vs time trade-off elicitation","author":"Myers","year":"2004"},{"issue":"2","key":"10.1016\/j.vaccine.2010.08.030_bib0170","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ygyno.2005.01.010","article-title":"Quality of life in long-term cervical cancer survivors","volume":"97","author":"Wenzel","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.vaccine.2010.08.030_bib0175","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/000348940511400701","article-title":"Use of the Pediatric Quality of Life Inventory to assess the health-related quality of life in children with recurrent respiratory papillomatosis","volume":"114","author":"Lindman","year":"2005","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10.1016\/j.vaccine.2010.08.030_bib0180","unstructured":"Weiss TW, Rosenthal SL, Zimet GD, Ma L, Good MB, Vichnin MD. Adherence with the quadrivalent HPV vaccine among insured US females. Poster presentation international papillomavirus conference, Malmo, Sweden; May 8\u201314, 2009."},{"issue":"36","key":"10.1016\/j.vaccine.2010.08.030_bib0185","first-page":"997","article-title":"National, state, and local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2008","volume":"58","author":"CDC","year":"2009","journal-title":"MMWR"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2010.08.030_bib0190","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0264-410X(02)00457-7","article-title":"Cost-effectiveness of hepatitis B vaccination of prison immates","volume":"21","author":"Pisu","year":"2002","journal-title":"Vaccine"},{"issue":"21","key":"10.1016\/j.vaccine.2010.08.030_bib0195","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","article-title":"Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2010.08.030_bib0200","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00005650-199806000-00002","article-title":"Toward consistency in cost-utility analyses: using national measures to create condition-specific values","volume":"36","author":"Gold","year":"1998","journal-title":"Med Care"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10011758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10011758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T20:59:53Z","timestamp":1544302793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10011758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":41,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0264410X10011758"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.08.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}